A phase II trial of the first-in-class angiotensin receptor neprilysin inhibitor, LCZ696, has shown that the compound may improve treatment of heart failure patients.
viaMedWire News
viaMedWire News
The India Cardiology 2.0 Medical Social Media Network
No comments:
Post a Comment